Latest news with #MindMaze
Yahoo
a day ago
- Business
- Yahoo
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Binding term sheet signed; transaction subject to customary conditions and approvals Closing expected in Q4 2025 GENEVA, SWITZERLAND / / July 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ("Relief" or the "Company"), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the execution of a binding term sheet for a proposed business combination with NeuroX Group SA ("NeuroX"), a privately held company that recently acquired the assets and operations of MindMaze - a recognized leader in digital neurotherapeutics and brain health technologies. The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families. NeuroX will contribute a clinically validated, risk-mitigated portfolio supported by multiple milestones achieved across technological development, regulatory approvals, and market access, as well as a solid network of pharmaceutical partners. Dr. Raghuram Selvaraju, chairman of the board of directors of Relief, commented: "By entering into this transaction, we intend to bring a global pioneer in digital neurotherapeutics to the public markets through the Relief ecosystem. NeuroX, which now operates the MindMaze platform, has a compelling business model, an established track record of innovation, and a distinctive technology that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. We believe this combination has the potential to create significant value for patients, clinicians, and shareholders. Importantly, it offers existing Relief shareholders the opportunity to participate in the growth of a scalable enterprise with potential to become a multi-billion-dollar company." Alexandre Capet, head of corporate development of NeuroX, commented: "The business combination with Relief presents a timely opportunity to build on the vision and ambition set by MindMaze on a global scale, accelerating our market presence and next phase of growth. Over the past decade, we have built a robust portfolio of clinically validated digital neurotherapeutics and invested heavily in commercial infrastructure, AI technology, and R&D. With increased visibility and a solid foundation in place, we believe this transaction comes at a pivotal inflection point in our journey. It positions us to scale more effectively as a publicly listed company and expand the reach of our breakthrough therapies." NeuroX and MindMaze OverviewNeuroX is a Swiss-based, commercial-stage company. In 2025, NeuroX acquired the operations and intellectual property of the legacy MindMaze group ("MindMaze"), including the MindMaze ® brand. MindMaze has developed first-of-its-kind neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services. The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients' home, to successfully address some of neurology's major unmet needs. NeuroX has already partnered with leading pharmaceutical companies that use its proprietary technology across multiple clinical trials. Over the last decade, MindMaze has invested more than USD 350 million to establish clinical evidence, demonstrate significant medico-economic outcomes, and market MindMaze's disease-modifying therapeutic platform across neurological diseases, including stroke, Parkinson's disease, and at-risk aging. In the United States, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training. Its R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer's disease/dementia. Moved by the mission to accelerate the brain's ability to recover, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair. For more information, visit . Transaction OverviewUnder the terms of the term sheet, NeuroX shareholders will exchange at closing all outstanding shares of NeuroX for newly issued shares of Relief. The transaction is based on agreed equity valuations of CHF 100 million for Relief, representing a significant premium to its current market capitalization, and CHF 1 billion for NeuroX. Post-closing, Relief shareholders are expected to own approximately 9% of the combined entity on a fully diluted basis, with NeuroX shareholders holding the remaining 91%. The combined entity's shares will continue trading on the SIX Swiss Exchange. The term sheet provides for full exclusivity during the negotiation and finalization of a definitive agreement, as well as a customary break fee, reflecting the commitment of both parties to advance the transaction. It also includes a one-year post-closing reset mechanism to adjust the ownership ratio within certain parameters based on the combined entity's market value at that time. The transaction remains subject, among other customary conditions, to the negotiation and execution of a definitive agreement, completion of satisfactory due diligence, approval by the shareholders of both companies, completion of concurrent financing by NeuroX, filing of regulatory documentation with the applicable securities authorities, and receipt of regulatory and stock exchange approvals. There can be no assurance that the transaction will be completed on the terms described herein or at all. The parties expect to finalize the definitive transaction agreement in Q3 2025, with closing anticipated in Q4 2025. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. The Company has access to a CHF 50 million equity commitment in the form of a share subscription facility with its largest shareholder, Global Emerging Markets (GEM). For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information provided on NeuroX and MindMaze within this press release is provided by NeuroX. Relief makes no representation or warranty as to the accuracy, completeness, or reliability of such information and disclaims any obligation or liability in connection with it. No offer or solicitation: This press release does not constitute (i) a prospectus within the meaning of the Swiss Financial Services Act or under any other applicable laws, (ii) a solicitation of proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (iii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Relief, NeuroX, or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the laws of such other jurisdiction. This press release should not be treated as offering material of any sort and is for information purposes only. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-06-2025
- General
- Yahoo
County schools challenge young learners at 'Insight Academy' camp
Tuesday morning, students in Sara Appleby's 'Mind Maze' class were working in pairs to solve 'Murdle' mimi detective puzzles at Deer Park Elementary School. 'We're using memory skills, language skills, deduction skills, process of elimination,' Appleby said. 'It's trying to get them to think differently,' Appleby said. 'They have to figure out a solution to a problem that's not obvious. They all solve it differently. They all have different strategies.' Although schools are out for the summer, the fourth and fifth graders in Appleby's class and others were busy trying out the Scientific Method by experimenting with food, building their skills with integers and learning about history by sticking their hands in water similar to the the icy ocean that surrounded the Titanic when the behemoth ocean liner met its fate in 1912. The classes were a hands-on collaborative learning experience that was anything but routine, which was intentional by Angie Gunter, Daviess County Public Schools' gifted and talented coordinator. Tuesday was the second day of DCPS' 'Insight Academy' summer day camp for gifted and talented students at Deer Park. The 24 students, who came from elementary schools across the district, were invited to participate based on their high scores in math and language arts assessment tests. While each of the elementary schools has a gifted and talented team that augments the traditional curriculum for promising students, the idea behind the camp is to challenge the students beyond what they traditionally receive in the classroom, Gunter said. 'We have middle school teachers who are teaching these kids,' Gunter said. The teachers proposed their own topics and crafted the classes. Having middle school instructors working with the students at the camp both lets the teachers get to know kids who will one day be in their classes, while also giving the students an idea of 'what's expected in middle school,' academically, Gunter said. The classes were designed to be hands-on and fun, Gunter said. 'These kids signed up to do math in the summer, and they love it,' she said. Brad Goodall, who was teaching the 'Math with a Twist' class, said the fourth and fifth graders would move through a curriculum during the week that would include some of the pre-algebra they will encounter in middle school. 'Because I teach middle school math, I know what they are going to need,' Goodall said, as they students busily played a competitive card game based on integers. 'We've had a good time working together. If you notice, they are not quiet.' The game was designed to be active and energetic for the gifted students. 'If they are not challenged, they get bored,' Goodall said. 'I'm trying to keep them as challenged as I can.' There was also a social element to the camp, Gunter said, as the students learned cooperation and collaboration by working together. 'Some of these kids are the ones that tend to dominate' their traditional classes, Gunter said. Part of the camp process is teaching 'all these dominant (students) to take turns,' Gunter said. 'Next year, we are going to expand to middle school' and have students from the middle schools as well, who will be taught by high school teachers. While already gifted students might not seem to need much help with school, providing hands-on and engaging content furthers the district's goals, Gunter said. 'By law, we are supposed to serve and help every kid grow,' Gunter said. Even a student already considered to be gifted can achieve more, she said. 'If we are not allowing the kids to reach their potential, we are not serving the students,' Gunter said.
